Serkan Kır and his team conducted a 6-year study addressing the prevention of weight and muscle loss associated with cancer, particularly in advanced stages. They identified that the “EDA2R” gene and “NIK” enzyme contribute to this loss, and by deactivating them, weight and muscle loss can be mitigated. Published in “Nature,” their research sheds light on mechanisms triggering muscle atrophy, holding promise for future treatments. Dr. Kır highlighted how cachexia affects patients’ quality of life and responses to treatments, stressing the need for drug development. The research was carried out over 6 years with the participation of a 7-person team, involving cancer patient tissue samples and genetically modified mice, revealing key insights into the mechanisms. The findings are expected to inspire further studies, extending beyond cancer to age-related muscle loss and other conditions, offering potential medical breakthroughs.
🔗 Link: [AA] Türk bilim insanından kanser tedavisini zorlaştıran kilo ve kas kaybına çözüm
🔗 Link: [HaberTürk] Türk bilim insanından kanser tedavisini zorlaştıran kilo ve kas kaybına çözüm
🔗 Link: [Cumhuriyet] Kanser tedavisini zorlaştıran kilo ve kas kaybına çözüm
